Arcadia Biosciences (RKDA) faces Nasdaq $1.00 bid-price deficiency and potential delisting risk
Rhea-AI Filing Summary
Arcadia Biosciences, Inc. reported that Nasdaq notified the company on August 4, 2026 that its common stock no longer meets the $1.00 per share Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The determination was based on the closing bid price over the 30 consecutive business days from June 22, 2026 to August 3, 2026. The stock will continue trading on Nasdaq under the symbol RKDA during an initial 180-day compliance period ending February 1, 2027. To regain compliance, the closing bid price must be at least $1.00 for at least ten consecutive business days, and Nasdaq may require a longer period. If still noncompliant, Arcadia may qualify for an additional 180-day period, potentially including a reverse stock split. The company states it will monitor its bid price and evaluate options, while cautioning there is no assurance it will regain or maintain Nasdaq compliance.
Positive
- None.
Negative
- Nasdaq bid-price deficiency notice received, indicating RKDA failed to meet the $1.00 minimum bid for 30 consecutive business days and faces potential delisting risk if compliance is not regained within allowed periods.
8-K Event Classification
2 items: 3.01, 9.01
2 items
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Minimum bid price requirement: $1.00 per share
Noncompliance measurement window: 30 consecutive business days
Initial compliance period: 180 calendar days
+2 more
5 metrics
Minimum bid price requirement
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) minimum bid price for continued listing
Noncompliance measurement window
30 consecutive business days
Period from June 22, 2026 to August 3, 2026 with closing bid below $1.00
Initial compliance period
180 calendar days
Time allowed to regain bid-price compliance, ending February 1, 2027
Price-restoration condition
10 consecutive business days
Required days with closing bid at or above $1.00 to regain compliance
Potential additional compliance period
180 calendar days
Possible second period if other Nasdaq listing standards are met
Key Terms
Minimum Bid Price Requirement, Nasdaq Listing Rule 5550(a)(2), Nasdaq Listing Rule 5810(c)(3)(A), reverse stock split, +1 more
5 terms
Minimum Bid Price Requirement regulatory
"which requires listed securities to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”)"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2)"
Nasdaq Listing Rule 5810(c)(3)(A) regulatory
"In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period"
reverse stock split financial
"including, if necessary, by effecting a reverse stock split"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Nasdaq Hearings Panel regulatory
"the Company would have the opportunity to appeal Nasdaq’s determination to a Nasdaq Hearings Panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What Nasdaq compliance issue did Arcadia Biosciences (RKDA) disclose?
Arcadia Biosciences disclosed it received a Nasdaq notice on August 4, 2026 for failing to meet the $1.00 minimum bid price requirement after its shares closed below that level for 30 consecutive business days.
How long does Arcadia Biosciences (RKDA) have to regain Nasdaq bid-price compliance?
Arcadia has an initial 180-day compliance period until February 1, 2027. During this time, its shares remain listed on The Nasdaq Capital Market while it works to restore its closing bid price.
What must Arcadia Biosciences (RKDA) do to regain Nasdaq minimum bid price compliance?
To regain compliance, Arcadia’s common stock must have a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days within the allowed compliance period.
Can Arcadia Biosciences (RKDA) receive more time beyond February 1, 2027 to fix its bid price?
Arcadia may receive an additional 180-day period if it meets other Nasdaq listing standards and notifies Nasdaq of its intent to cure the deficiency, potentially including a reverse stock split.
Will Arcadia Biosciences (RKDA) be immediately delisted from Nasdaq due to this notice?
No. The notice has no immediate effect on Arcadia’s listing. The common stock continues to trade on The Nasdaq Capital Market under symbol RKDA during the compliance period.
What options is Arcadia Biosciences (RKDA) considering to address the Nasdaq deficiency?
Arcadia states it will monitor the closing bid price and evaluate options to regain compliance, which may include, if necessary, effecting a reverse stock split during the allowed timeframe.